AAP
CLDX icon

Ardsley Advisory Partners’s Celldex Therapeutics CLDX Stock Holding History

Ardsley Advisory Partners’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-37,667
Closed -$7.32M – 198
2014
Q3 		$7.32M Buy
37,667
+4,667
+14% +$1.02M 0.97% 32
2014
Q2 		$8.08M Buy
33,000
+5,700
+21% +$1.29M 1.03% 32
2014
Q1 		$7.24M Buy
27,300
+3,500
+15% +$1.34M 1.08% 31
2013
Q4 		$8.64M Buy
23,800
+6,133
+35% +$2.36M 1.15% 23
2013
Q3 		$9.39M Sell
17,667
-9,666
-35% -$3.31M 1.92% 17
2013
Q2 		$6.4M Buy
+27,333
New +$5.38M 1.4% 26

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ardsley Advisory Partners's CLDX Position: Q4 2014 in Review

Ardsley Advisory Partners sold out of Celldex Therapeutics (CLDX) in Q4 2014, closing a stake of 37,667 shares — an estimated $7.32M sold.

Ardsley Advisory Partners first reported a position in CLDX in Q2 2013 and held it in 6 quarters. The position peaked at $9.39M in Q3 2013. 163 funds tracked by Wall St. Rank hold CLDX as of Q4 2014.

  • Ardsley Advisory Partners reported no remaining Celldex Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Ardsley Advisory Partners sold 37,667 Celldex Therapeutics shares in Q4 2014, an estimated $7.32M.
  • Ardsley Advisory Partners first reported a position in Celldex Therapeutics in Q2 2013 and held it in 6 quarters.
  • Ardsley Advisory Partners's Celldex Therapeutics position peaked at $9.39M in Q3 2013.
  • 163 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2014.

Based on Ardsley Advisory Partners's 13F filing for Q4 2014, filed 17 Feb 2015.